Vision
Integrity, Innovation, and Quality
ExoOne was founded on December 22, 2020, by Dr. Lin, Tzou-Yien with a vision of global expansion, innovation, and ethical business practices in the biomedical industry. The company is dedicated to developing the clinical applications of exosomes and focusing on treating degenerative diseases. The company owns multiple exclusive patents on exosome technologies and aims to become the world’s leading biotech center in anti-aging and rejuvenation.
In March 2023, ExoOne spearheaded the establishment of the “Taiwan Alliance for Extracellular Vesicles”. The goal is to integrate the entire industry chain—from upstream research and academia to midstream clinical applications and downstream commercialization—fostering industry-wide collaboration. ExoOne aspires to establish the exosome industry as Taiwan's next major technological stronghold by bringing together industry, government, and academia.
Former Minister of Health and Welfare
PIONEERS
Pioneering the Future, Leading with Innovation, Expanding Globally
ExoOne Bio. Co., Ltd. is Taiwan's first exosome new drug development company. Founded by former Minister of Health and Welfare, Dr. Lin, Tzou-Yien, at the end of 2020, the company brings together experts from the pharmaceutical industry, the Taiwan Society for Extracellular Vesicles (TSEV), and product development specialists. Guided by the corporate philosophy of “Pioneering the Future, Leading with Innovation, and Expanding Globally,” ExoOne is built on a solid foundation of medical expertise and extensive industry, government, and academic experience.
With a mission to utilize high-quality exosome biotech products for treating degenerative diseases and promoting healthy aging, ExoOne aspires to become the world's leading biotech center in anti-aging and rejuvenation.
Exosome Purification Technology Leading the World
Recognizing the immense biomedical potential of exosomes in disease diagnosis, drug delivery, and treatment, ExoOne has developed unique core technologies for exosome isolation, purification, and characterization. The company has achieved industry-leading purity, activity, and production efficiency levels, surpassing international standards.
In 2021, ExoOne’s exosome new drug was recognized as a benchmark project by Taiwan’s Center for Drug Evaluation (CDE). ExoOne will collaborate with the government to establish regulatory standards for exosome-based new drugs, positioning Taiwan at the forefront of the rapidly advancing global biotech industry.
Breaking Treatment Barriers: A New Era for Degenerative Disease Therapies
As the global population ages, the prevalence of degenerative diseases continues to rise. ExoOne is dedicated to developing new drugs for degenerative diseases with the support of leading medical and academic institutions. Through industry-academia collaboration, the company is advancing research into degenerative disease treatments and accelerating the development of new therapies with the help of expert consultants. ExoOne’s goal is to enhance human health and support healthy aging worldwide.
Biotech Revolution
Integrity in Business, Leading the Future of Global Biotechnology
ExoOne upholds the principles of integrity and ethical business practices, producing high-purity exosome-based new drugs and developing exosome-infused skincare products to benefit a wider audience. The company is committed to maintaining the highest manufacturing and management standards while continuously innovating to align with global advancements. As a pioneering biotech company in anti-aging and regenerative medicine, ExoOne aims to lead Taiwan’s biotech industry onto the global stage.
-
October 2024
Radiation-labeled exosome animal studies showed accumulation in the liver and spleen, published in the Biomedical Journal. -
May 2024
•Launch of ExoOne's exosome haircare product “ExoHair Essence”.
•Signed a Memorandum of Understanding (MOU) with Drip Hydration (Vietnam). -
April 2024
•The Taiwan Ministry of Health and Welfare (MOHW) approved ExoOne's human umbilical cord mesenchymal stem cell (MSC) exosomes as an ingredient for cosmetic skincare products.
•ExoOne’s MSC exosomes received International Nomenclature of Cosmetic Ingredients (INCI) certification.
•Launch of ExoOne's exosome skincare products, including La Première Rejuvenation Ampoule, Jour Un Flawless Essence, Jour Un Princess Whitening Mask, and La Première ExoMuse Solution. -
December 2023
•Signed MOUs with KL International Healthcare Centre Sdn Bhd (Malaysia) and MediGroup (Vietnam).
•Published findings on MSC exosomes reducing skin inflammation in the International Journal of Molecular Sciences. -
September 2023
Established presence in the Taipei Biotechnology Park. -
June 2023
Awarded a new skincare product patent. -
March 2023
Recognized by the Ministry of Economic Affairs as a certified biotech medical company. -
December 2022
Awarded the 19th National Innovation Award (Enterprise Innovation Award in Specialized Materials & Biotech Category) -
October 2022
•Published research on anti-aging, antioxidant, and anti-inflammatory properties in the Antioxidants Journal.
•Secured exclusive patents and technology licenses from Tzu Chi University and MacKay Memorial Hospital. -
July 2022
Completed human clinical trials for skincare efficacy. -
May 2022
Industry-academia collaborations with Tzu Chi University and Kaohsiung Medical University. -
January 2022
Signed a CDMO agreement with Taibao Biotech to accelerate the standardization of cell manufacturing and exosome production. -
October 2021
Industry-academia collaborations with National Taiwan University, Hungkuang University, China Medical University, and Chang Gung University. -
August 2021
•ExoOne's new exosome drug was designated a benchmark project by the CDE (Taiwan Center for Drug Evaluation).
•Established an independent laboratory and an R&D center.
-
December 2020
Company founded in Linkou Startup Park.
- EducationBachelor's Degree in Medicine, Taipei Medical Colleg、Pediatric Infectious Disease Research Fellow, State University of New York at Buffalo School of Medicine、Pediatric Infectious Disease Research Fellow, University of Texas Southwestern Medical Center at Dallas
- Current PositionsHonorary Director, Chang Gung Children's Medical Center、Distinguished Professor, Chang Gung University、Chairman, ExoOne Bio. Co., Ltd.
- ExperienceDeputy Minister, Ministry of Health and Welfare、Chairman, National Health Research Institutes、President, Taiwan Pediatric Association、President, Taiwan Infectious Diseases Society、President, Chang Gung Children's Hospital、Professor of Pediatrics, Chang Gung University、Chairman, Hsin Hospital
- EducationMaster's Degree, Institute of Pharmacology, Yang Ming Chiao Tung University、Executive MBA, Baruch College, City University of New York (CUNY)、Bachelor's Degree in Pharmacy, Taipei Medical College
- ExpertiseMarket Development & Marketing、Pharmacology
- ExperienceSenior Director, Boehringer Ingelheim (France)、Franchise Lead, Critical Care & New Drug Development, TTY Biopharm、Acting Director, Critical Care Business Unit, MSD Taiwan (Merck), Franchise Lead, Best Marketing Employee of the Year, Best Team of the Year, MSD Taiwan、Senior Manager, New Drug Development, Pfizer Taiwan、Associate Manager, Clinical Trials & Marketing, GlaxoSmithKline (GSK) Taiwan
- EducationBachelor's Degree in Medicine, National Taiwan University、Master's Degree in Law, Soochow University、Certificate Medical Professional issued by IFPMA 、and King's College, London
- ExpertiseInternal Medicine、Infectious Diseases、Pharmaceutical Industry: Medical & Clinical、Regulatory Affairs、Pharmacovigilance、Quality Control/Assurance、Medical Information、Outcomes Research
- ExperienceConsultant, Adimmune Corporation、Consultant, Anterogen Corporation、Director, Strategy Planning & Development, Asian Fungal Working Group (AFWG)、Senior Regional Medical Director, Asia-Pacific, Pfizer、Director, Infectious Diseases Department, Far Eastern Memorial Hospital、Attending Physician & Consultant, Infectious Diseases Department, Hsinchu Cancer Center Hospital、Attending Physician, Infectious Diseases Department, National Taiwan University Hospital
- EducationMBA, Da-Yeh University, Taiwan、BBA in Business Mathematics, Soochow University, Taiwan
- ExpertiseFinancial Reporting、Corporate Governance、Financial Management、IPO Process
- Professional CertificationsCPA Australia
- ExperienceGroup CFO, Guardforce AI Co., Limited (NASDAQ-listed)、Executive Vice President, Summi (Group) Holdings Limited (HKEX-listed)、CFO, China Grand Star Luxury Cars Investment Holdings Limited、Vice President, Taipei Fubon Commercial Bank、Assistant Vice President, Bank Sinopac
- EducationMaster's Degree, Institute of Medical Science, Taipei Medical University、Ph.D., Institute of Biotechnology, National Tsing Hua University
- ExpertiseProtein & Exosome Process Purification、Large-Molecule Process Optimization、GTP Specification Development
- ExperiencePostdoctoral Researcher, National Health Research Institutes、R&D Lead, Kyber Biomed Group
- EducationPh.D., Institute of Molecular and Cellular Biology, National Tsing Hua University
- ExpertiseLarge-Molecule Drug Manufacturing Development、Process Scale-up、Bioreactors、Data Analysis
- ExperienceAssociate Researcher, EirGenix, Inc.、Project Deputy Manager, Panion & BF Biotech, Inc.
- EducationBachelor's Degree in Medicine, Taipei Medical Colleg、Pediatric Infectious Disease Research Fellow, State University of New York at Buffalo School of Medicine、Pediatric Infectious Disease Research Fellow, University of Texas Southwestern Medical Center at Dallas
- Current PositionsHonorary Director, Chang Gung Children's Medical Center、Distinguished Professor, Chang Gung University、Chairman, ExoOne Bio. Co., Ltd.
- ExperienceDeputy Minister, Ministry of Health and Welfare、Chairman, National Health Research Institutes、President, Taiwan Pediatric Association、President, Taiwan Infectious Diseases Society、President, Chang Gung Children's Hospital、Professor of Pediatrics, Chang Gung University、Chairman, Hsin Hospital
- Current PositionsChairman, Shin Hwa Wool Textile Co., Ltd.、Former Chairman, Taiwan Wool Textile Industry Association、Former Board Member, Taiwan Textile Research Institute、Board Member, Taiwan Brain Disease Prevention Foundation、Honorary President, Alumni Association of Textile & Molecular Science Engineering, National Taipei University of Technology
- EducationBachelor's Degree in Medicine, Kaohsiung Medical University
- Current PositionsFounder & Chairman, Anfa Medical Cell Bank、Founder & President, Taipei Anfa Anti-Aging Clinic、Founding President, Rotary Club of Taipei Antong、Honorary President, Taiwan Anti-Aging & Regenerative Medicine Association
- ExperienceChief Expert Physician, A4M & WAAAM (American & World Anti-Aging Medicine Association) Asia、Vice President, International Anti-Aging Medicine Association、Chief Resident, Pediatric Surgery, Columbia University Medical Center, New York、Director, Pediatric Surgery, Chang Gung Memorial Hospital
- EducationDoctor of Medicine (MD), Boston University, USA
- Current PositionsChief Operating Officer, Hsiao Chung-Cheng Medical System、General Manager, Zhu San Industrial Co., Ltd.
- ExperienceIndependent Director, Magnetic Biotech Co., Ltd.、CEO & COO, International Digital Health Company、Independent Director, Sheng Hong Pharmaceutical Co., Ltd.、Deputy COO, Show Chwan Medical System、Attending Physician, Obstetrics & Gynecology, Harvard Medical School Teaching Hospital, USA
